Corvus Pharmaceuticals Reports Positive Phase 1 Data for Soquelitinib in Atopic Dermatitis, Exceeding Expectations

Cohort 4 of the Phase 1 trial showed a mean 70-72% EASI reduction with soquelitinib 200 mg twice daily at day 56, vs 40% for placebo123.

75% of soquelitinib patients achieved EASI 75, 25% EASI 90, and 33% IGA 0/1, compared to 20%, 0%, and 0% on placebo12.

Efficacy seen in patients previously treated with dupilumab and JAK inhibitors, with deepening responses from day 28 to 5612.

Favorable safety profile with only Grade 1-2 adverse events and no serious events1.

Biomarkers support ITK inhibition:
reductions in IL-4, IL-5, IL-17, TARC, Th2 cells; increases in Treg cells1.

Phase 2 trial planned for Q1 2026 in moderate to severe atopic dermatitis patients who failed prior therapies12.

Data released January 20, 2026, leading to positive stock reaction57.

Sources:

1. https://www.stocktitan.net/sec-filings/CRVS/8-k-corvus-pharmaceuticals-inc-reports-material-event-2d96db663eea.html

2. https://www.globenewswire.com/news-release/2026/01/20/3221554/0/en/Corvus-Pharmaceuticals-Announces-Positive-Data-from-Cohort-4-Confirming-Results-for-Placebo-Controlled-Phase-1-Clinical-Trial-of-Soquelitinib-for-Atopic-Dermatitis.html

3. https://www.dermatologytimes.com/view/soquelitinib-phase-1-data-show-sustained-clinical-improvement-with-extended-treatment-in-ad

5. https://www.tradingview.com/news/tradingview:36cc799b90340:0-corvus-pharmaceuticals-announces-positive-phase-1-trial-results-for-soquelitinib/

7. https://www.investing.com/news/stock-market-news/corvus-pharmaceuticals-stock-soars-after-positive-atopic-dermatitis-trial-data-93CH-4454906